Abstract
Sarcomas are tumors of mesenchymal origin that remain with poor prognosis. This review highlights some emerging predictive biomarkers that could drive personalized therapy, focusing on KIT, TP53, MDM2, CDK4 mutations, PRAME, INI1 and NF1. Research shows that there is a role for imatinib in some gastrointestinal stromal tumors with KIT mutations, and the TP53 mutation may someday serve as a biomarker to assist decision-making for neoadjuvant chemotherapy. Amplifications of MDM2 and CDK4 are currently targets for new therapeutical drugs. For PRAME, there is perspective for tumors with high CTA expression with some T-cell mediated therapies. INI1 loss can be a target for tazemetostat treatment in patients with advanced epithelioid sarcoma, and studies have shown a role for Selumetinib in patients with NF1 mutations related tumors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
